巴瑞替尼治疗类风湿关节炎中位3年安全性更新整合分析
4 mg和2 mg巴瑞替尼与安慰剂相比,死亡、恶性肿瘤、严重感染和主要不良心血管事件发生率无显著差异,但带状疱疹和治疗中出现感染发生率较高。静脉血栓栓塞事件发生率与既往报告一致,未发现新的安全性信号。
要点
- 巴瑞替尼4 mg和2 mg与安慰剂相比,死亡、恶性肿瘤、严重感染和主要不良心血管事件发生率无显著差异。
核心结论
- 巴瑞替尼2 mg和4 mg在最长近7年暴露中维持与早期分析相似的安全性,未发现新安全性信号。
研究设计与样本
- 整合9项3期、2期和1b期临床试验及1项长期扩展研究,数据截至2018年2月13日,最长360周。
- 安慰剂对照数据集纳入2836例患者:安慰剂组1215例(451患者年),巴瑞替尼2 mg组479例(186患者年),4 mg组1142例(472患者年),至第24周。
- 2-4 mg扩展数据集纳入958例患者,2 mg和4 mg组各479例。
主要发现
- 巴瑞替尼4 mg或2 mg与安慰剂比较,以及4 mg与2 mg比较,死亡、恶性肿瘤、严重感染或主要不良心血管事件发生率均无显著差异。
关键数值与推荐
- 2-4 mg扩展数据集中未发现巴瑞替尼4 mg组静脉血栓栓塞事件发生率高于2 mg组的迹象。
临床怎么用
- 长期使用巴瑞替尼治疗活动性类风湿关节炎时,应关注带状疱疹和治疗中出现感染的风险。
- 巴瑞替尼治疗中静脉血栓栓塞事件发生率与既往报告一致,无需额外调整监测策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2, approved for the treatment of patients with active rheumatoid arthritis. Because baricitinib, like other disease-modifying antirheumatic drugs, is used chronically, continuous assessment of its long-term safety profile is important. Here we provide updated data supporting the existing safety profile of baricitinib in this patient population. METHODS: In this safety analysis, integrated data were included from nine phase 3, phase 2, and phase 1b clinical trials, and one long-term extension study with data up to 360 weeks, ending Feb 13, 2018. We analysed three integrated datasets, the largest of which was the all-bari-RA dataset, which includes patients who received any dose of baricitinib. We compared the safety of baricitinib with placebo on the basis of data from seven studies with baricitinib 4 mg and placebo and four studies with baricitinib 2 mg, including placebo to week 24 (placebo-controlled dataset). We did a dose-response assessment based on four studies with baricitinib 2 mg and 4 mg, including long-term extension data (2-4 mg extended dataset). We did an exploratory analysis of deaths and venous thromboembolic events in a subset of data from the all-bari-RA dataset that included patients who had ever taken baricitinib 2-mg or baricitinib 4-mg. We did an analysis for malignancies (excluding non-melanoma skin cancer) in the as-randomised population (patients not censored at rescue or dose change). FINDINGS: We collected data for 3770 patients who were given baricitinib for 10 127 patient-years of exposure in the all-bari-RA dataset (median 1115 days [IQR 426-1441], maximum 2520 days). The placebo-controlled dataset comprised 2836 patients, with 1215 in the placebo group, with 451 patient-years of exposure data; 479 in the baricitinib 2 mg group, with 186 patient-years of exposure data; and 1142 in the baricitinib 4 mg group, with 472 patient-years of exposure data. The 2-4 mg extended dataset comprised 958 patients, with 479 in both the 2 mg and 4 mg groups. No significant differences were seen for baricitinib 4 mg or 2 mg versus placebo, or for 4 mg versus 2 mg in the incidence of death, malignancy, serious infection, or major adverse cardiovascular events. Incidence of herpes zoster per 100 patient-years was higher for baricitinib (4 mg: 4·4 [95% CI 2·7-6·7]; 2 mg: 3·1 [1·1-6·8]) versus total placebo group (1·1 [0·4-2·5]), as were treatment-emergent infections (4 mg: 89·7 [81·3-98·6]; 2 mg: 84·0 [71·3-98·2] vs placebo 75·4 [67·6-83·9]). Consistent with previous reports, incidences in the all-bari-RA dataset for venous thromboembolic events was 0·5 (95% CI 0·4-0·6) per 100 patient-years, deep-vein thrombosis was 0·3 (0·2-0·5) per 100 patient-years, and pulmonary embolism was 0·2 (0·2-0·4) per 100 patient-years. Incidences of malignancy (excluding non-melanoma skin cancer) in the 2-4 mg extended dataset were 0·8 (0·4-1·5) per 100 patient-years for baricitinib 2 mg and 1·0 (0·5-1·7) per 100 patient-years for baricitinib 4 mg, without censoring patients who had dose changes or received rescue treatment. We found no indication of higher incidence of venous thromboembolic events in the baricitinib 4 mg group compared with the 2 mg group in the 2-4 mg extended dataset. INTERPRETATION: In this updated integrated analysis of patients with active rheumatoid arthritis exposed to baricitinib for a maximum of almost 7 years, baricitinib 2 mg and 4 mg maintained a similar safety profile to earlier analyses. No new safety signals were identified. Patients in the long-term extension study continue to be followed up to date. FUNDING: Eli Lilly and Company, under license from Incyte Corporation.
引用
- Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2020. PMID: 38273598. doi:10.1016/S2665-9913(20)30032-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。